Business
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrol
About this update from Antengene Corporation Limited
[{"type":"text","content":"- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy.","length":125,"tagName":"p"},{"type":"text","content":"SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.","length":618,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Antengene Corporation Limited)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Antengene Corporation Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":170,"url":"https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5j2U0HrCj8zISzT4Iv1xLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583","width":400,"height":170}},"href":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), Antengene presented the latest data from its Phase I/II CLINCH study. Results showed an objective response rate (ORR) of 42.9% and a disease control rate (DCR) of 95.2% in patients with moderate to high CLDN18.2 expression (IHC 2+ ≥ 20%). Additionally, the study demonstrated an ORR of 30.0% and a DCR of 50.0% in patients with low CLDN18.2 expression (IHC 2+ < 20%). ATG-022 also exhibited a favorable safety profile and extended treatment durations, with no observed cases of ophthalmological or neurological toxicities, nor interstitial lung disease.","length":657,"tagName":"p"},{"type":"text","content":"ATG-022 is uniquely positioned in the global landscape, with data supporting meaningful efficacy across all levels of Claudin...